Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia

Robert H. Mak, Wai Cheung, Roger D. Cone, Daniel Marks

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60%. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome - more accurately described as 'cachexia' - manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-α, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.

Original languageEnglish (US)
Pages (from-to)527-534
Number of pages8
JournalNature Clinical Practice Nephrology
Volume2
Issue number9
DOIs
StatePublished - Sep 4 2006

Fingerprint

Cachexia
Adipokines
Cytokines
Uremia
Melanocortins
Resistin
Basal Metabolism
Ghrelin
Adiponectin
Anorexia
Leptin
Acidosis
Interleukin-1
Malnutrition
Chronic Kidney Failure
Blood Proteins
Interleukin-6
Tumor Necrosis Factor-alpha
Hormones
Inflammation

Keywords

  • Inflammation
  • Leptin
  • Melanocortin
  • Nutrition
  • Uremia

ASJC Scopus subject areas

  • Nephrology

Cite this

Mechanisms of disease : Cytokine and adipokine signaling in uremic cachexia. / Mak, Robert H.; Cheung, Wai; Cone, Roger D.; Marks, Daniel.

In: Nature Clinical Practice Nephrology, Vol. 2, No. 9, 04.09.2006, p. 527-534.

Research output: Contribution to journalArticle

Mak, Robert H. ; Cheung, Wai ; Cone, Roger D. ; Marks, Daniel. / Mechanisms of disease : Cytokine and adipokine signaling in uremic cachexia. In: Nature Clinical Practice Nephrology. 2006 ; Vol. 2, No. 9. pp. 527-534.
@article{55659003a31f4c1da1daac7d5ece7bff,
title = "Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia",
abstract = "Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60{\%}. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome - more accurately described as 'cachexia' - manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-α, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.",
keywords = "Inflammation, Leptin, Melanocortin, Nutrition, Uremia",
author = "Mak, {Robert H.} and Wai Cheung and Cone, {Roger D.} and Daniel Marks",
year = "2006",
month = "9",
day = "4",
doi = "10.1038/ncpneph0273",
language = "English (US)",
volume = "2",
pages = "527--534",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Mechanisms of disease

T2 - Cytokine and adipokine signaling in uremic cachexia

AU - Mak, Robert H.

AU - Cheung, Wai

AU - Cone, Roger D.

AU - Marks, Daniel

PY - 2006/9/4

Y1 - 2006/9/4

N2 - Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60%. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome - more accurately described as 'cachexia' - manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-α, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.

AB - Clinical wasting is an important risk factor for mortality in uremic patients and is reported to have a prevalence of 30-60%. 'Malnutrition' is often inappropriately used to describe a group of nutritional abnormalities in uremic patients, which are characterized by anorexia, increased basal metabolic rate, loss of lean body mass, and declining levels of serum proteins. This syndrome - more accurately described as 'cachexia' - manifests as growth failure in children with uremia. Acidosis and inflammation are important causes of uremic cachexia but the underlying molecular mechanism is not well understood. Concentrations of circulating cytokines, such as leptin, tumor necrosis factor-α, interleukin-1, and interleukin-6, are elevated in patients with end-stage renal disease and correlate with the degree of cachexia in these individuals. Other energy-modulating hormones such as ghrelin, and adipokines such as adiponectin and resistin, are also perturbed in uremia and could contribute to nutritional abnormalities. We recently showed that elevated levels of circulating cytokines might be an important contributor to uremia-associated cachexia via signaling through the central melanocortin system. Small-molecule melanocortin antagonists, which are biologically active when administered orally or intraperitoneally, are now available and have been used successfully to ameliorate experimental cachexia. These findings could form the basis of a novel therapeutic strategy for uremic cachexia.

KW - Inflammation

KW - Leptin

KW - Melanocortin

KW - Nutrition

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=33748331209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748331209&partnerID=8YFLogxK

U2 - 10.1038/ncpneph0273

DO - 10.1038/ncpneph0273

M3 - Article

C2 - 16941045

AN - SCOPUS:33748331209

VL - 2

SP - 527

EP - 534

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 9

ER -